Welcome to our dedicated page for Plexus SEC filings (Ticker: PLXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Plexus Corp (NASDAQ: PLXS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Plexus files periodic and current reports as a Wisconsin corporation with Commission File Number 001-14423.
Among the key documents available are current reports on Form 8-K, which Plexus uses to furnish press releases announcing quarterly and annual financial results. These filings typically include information on revenue, operating margin, earnings per share, non-GAAP performance measures, return on invested capital, free cash flow and other financial metrics, as well as commentary on business conditions and program wins.
Through this page, users can track how Plexus reports its results for fiscal quarters and years, including references to its geographic segments in the Americas, Asia-Pacific and Europe, Middle East and Africa regions, and its focus on Aerospace/Defense, Healthcare/Life Sciences and Industrial market sectors. Filings also confirm corporate details such as state of incorporation and principal corporate location.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand the implications of each report. Real-time updates from the SEC’s EDGAR system, along with structured access to forms such as 8-K and other periodic reports, make it easier to review Plexus’ regulatory history and monitor ongoing disclosures related to PLXS.
Plexus Corp executive Patrick J. Jermain, Exec. VP & CFO, reported multiple equity transactions in company stock. On January 30, 2026, 9,360 Restricted Stock Units vested and settled into an equal number of Plexus common shares under the company’s 2016 Omnibus Incentive Plan. On the same date, 4,433 shares were surrendered to cover tax obligations at a price of $199.33 per share. On February 3, 2026, he sold 4,841 common shares at $204.01 per share. Following these transactions, he held 20,469 shares directly and 3,719 shares indirectly through the Plexus Corp. 401(k) Retirement Plan.
A trust named TODD P KELSEY & KELLY M LIV T U/A DTD 03/02/2009 has filed a Form 144 indicating an intent to sell 8,120 common shares of the PLXS issuer through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ. The planned sale has an stated aggregate market value of 1,669,880.20, with 26,774,415 shares outstanding for the issuer. These shares were acquired as restricted stock from the issuer on 01/25/2024. Over the past three months, the same trust reported selling 2,000 common shares for 290,200.00 on 11/05/2025 and another 2,000 shares for 287,000.00 on 11/04/2025.
Plexus Corp. insider Patrick Jermain has filed a Form 144 notice to sell up to 4,841 shares of Plexus common stock. The planned sale, with an aggregate market value of $987,612.41, is to be executed through Morgan Stanley Smith Barney LLC on or around February 3, 2026 on the NASDAQ market. The shares come from restricted stock acquired on January 25, 2019 and performance shares acquired on November 13, 2024. Over the prior three months, Jermain also sold 2,000 Plexus common shares for gross proceeds of $287,070.00.
Plexus Corp. investor filed a Form 144 indicating an intent to sell 5,000 shares of common stock. The proposed sale is to be executed through Robert W. Baird & Co. on the NASDAQ, with an aggregate market value of $996,650 for the shares listed in the notice.
The table notes that 26,713,916 shares of Plexus common stock were outstanding, providing context for the planned sale. The 5,000 shares were originally acquired on 11/30/1999 in a transaction involving a Family Trust and David and Constance Foate, with the form listing an approximate sale date of 02/02/2026.
A shareholder of PLXS has filed a Rule 144 notice to sell 926 shares of common stock, with an aggregate market value of $189,756.01. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 02/02/2026.
The securities were acquired as restricted stock from the issuer on 01/30/2026, and the same date is listed as the payment date. Shares outstanding for this class are reported at 26,774,415, providing context for the relative size of the proposed sale.
Plexus Corp. filed a current report to share that it has released financial results for its fiscal first quarter ended January 3, 2026. The company announced these results on January 28, 2026 and attached the full earnings press release as an exhibit to the report.
The press release is included as Exhibit 99.1, allowing investors to review detailed information about Plexus Corp.’s operations and financial condition for the quarter. The report itself is primarily a formal notice that these quarterly results have been publicly released.
Plexus Corp. director reports amended stock gift transaction
A Plexus Corp. (PLXS) director reported the bona fide gift of 700 shares of Plexus common stock. After this gift, the director beneficially owns 8,165 shares in direct form. This amendment corrects the transaction date to November 21, 2025, clarifying that an earlier attempted transfer on November 4, 2025 did not go through due to an administrative error and the shares were returned before being successfully transferred on the corrected date.
Plexus Corp. (PLXS) executive Oliver K. Mihm, Exec VP & COO, reported several equity transactions in company stock. On 11/12/2025, 5,023 shares of common stock were acquired following the vesting and settlement of performance stock units, while 2,361 shares were disposed of at a price of $146.24 per share, typically reflecting shares withheld or sold to cover taxes. Mihm also made a bona fide gift of 1,100 shares of Plexus common stock.
The filing shows 981 shares of Plexus common stock held indirectly in the company’s 401(k) Retirement Plan. In addition, 1,383 new performance stock units were credited based on company performance. The company disclosed that 138% of the economic return portion of performance stock units granted in fiscal 2023 vested, while the portion tied to relative total shareholder return versus the S&P 400 Index has not yet completed its three-year performance period.
Plexus Corp. filed its Annual Report (10-K) for the fiscal year ended September 27, 2025. The company designs, manufactures and services highly complex products across Aerospace/Defense, Healthcare/Life Sciences, and Industrial markets, operating 26 facilities with a global team of over 20,000. Management targets long-term compounded annual revenue growth of 9–12% and a 15% ROIC; Plexus’ internal WACC for fiscal 2025 was 8.9%.
Customer exposure is diversified: approximately 190 customers in fiscal 2025 and no single customer over 10% of sales. Net sales mix in 2025 was 17% Aerospace/Defense, 40% Healthcare/Life Sciences, and 43% Industrial. Shares outstanding were 27,121,994 as of March 29, 2025; as of November 10, 2025, there were 26,774,415 shares outstanding. The company highlights robust certifications (including ISO and FDA-related capabilities) and details risk factors such as supply chain constraints, regulatory complexity, competition, and geopolitical volatility.
Plexus Corp (PLXS) Executive VP & CFO reported insider transactions. On 11/11/2025, he sold 2,000 shares of common stock at $143.535. On 11/12/2025, 6,458 Performance Stock Units (PSUs) were converted to common stock (code M), and 3,036 shares were withheld to cover taxes at $146.24 (code F).
After these transactions, he held 20,383 shares directly and 3,719 shares in the company 401(k). The filing notes that, based on company performance for economic return goals over three years, 138% of the fiscal 2023 PSU tranche vested; the relative TSR portion’s performance period has not concluded.